|
|
AI-Optimized RNA-Binding Library |
|
In recent years, structured RNAs have become tractable drug targets, enabling the discovery of selective modulators for riboswitches, long noncoding RNAs, G-quadruplexes, and RNA–protein complexes.
Breakthrough advances in library design, screening methodologies, and AI-based prioritization have expanded the scope of RNA-targeted drug discovery (Kovachka et al., Nat Rev Chem 2024; Lundquist et al., SLAS Discovery 2025; Morishita, ChemMedChem 2022; Momentum Bio, 2024).
Modern RNA-focused screening now combines:
-
SPR/BLI for kinetic profiling and specificity ranking,
-
AI-guided virtual enrichment to prioritize compounds with high “RNA-likeness” before experimental testing (Graff et al., Chem Sci 2020; Cao et al., Nat Mach Intell 2023).
|
|
Read more...
|
|
OTAVA Dual HDAC1/mTOR Inhibitors Library |
|
Histone deacetylase 1 (HDAC1; also known as GON-10, RPD3, or KDAC1) is a key epigenetic regulator involved in chromatin remodeling and gene expression. Aberrant HDAC1 activity has been implicated in tumorigenesis, and it is widely recognized as a high-value target for cancer therapy due to its role in promoting oncogenic transcriptional programs.
The mechanistic target of rapamycin (mTOR; also referred to as FRAP1, RAFT1, or RAPT1) is a central serine/threonine kinase that integrates nutrient and growth factor signals to regulate cell growth, proliferation, metabolism, and autophagy. Hyperactivation of mTOR signaling is a hallmark of various malignancies, contributing to uncontrolled tumor cell survival and resistance to therapy.
|
|
Read more...
|
|
|
|
|
|
HOME
Overview
